195 Recruiting Melanoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Melanoma
Related Conditions
Top Recruiting Melanoma Studies
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
📍 University of California San Francisco — San Francisco, California
View Study & Checklist ➔An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
📍 University of Arizona — Tucson, Arizona
View Study & Checklist ➔Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
📍 Centro Oncologico Korben — CABA, Buenos Aires
View Study & Checklist ➔Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
📍 Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica, California
View Study & Checklist ➔NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
📍 Adventist Health System/Sunbelt, Inc. — Orlando, Florida
View Study & Checklist ➔Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
📍 University of Louisville — Louisville, Kentucky
View Study & Checklist ➔A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
📍 The Angeles Clinic — Los Angeles, California
View Study & Checklist ➔War on Melanoma™ Public Health & Education Campaign
📍 OHSU Knight Cancer Institute — Portland, Oregon
View Study & Checklist ➔A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
📍 The Angeles Clinic and Research Institute - California — Los Angeles, California
View Study & Checklist ➔A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
📍 Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania
View Study & Checklist ➔A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
📍 California Pacific Medical Center Research Institute — San Francisco, California
View Study & Checklist ➔Treating Patients With Melanoma and ALK Alterations With Ensartinib
📍 Memorial Sloan Kettering Monmouth — Middletown, New Jersey
View Study & Checklist ➔Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)
📍 Intermountain Medical Center — Murray, Utah
View Study & Checklist ➔Transfer of Genetically Engineered Lymphocytes in Melanoma Patients
📍 Loyola University Medical Center — Maywood, Illinois
View Study & Checklist ➔A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
📍 Local Institution - 0125 — Phoenix, Arizona
View Study & Checklist ➔Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
📍 The Angeles Clinic and Research Institute — Los Angeles, California
View Study & Checklist ➔Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
📍 The University of Texas MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
📍 Duke Cancer Center — Durham, North Carolina
View Study & Checklist ➔Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
📍 UC San Diego — La Jolla, California
View Study & Checklist ➔Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
📍 Local Institution - 0088 — Birmingham, Alabama
View Study & Checklist ➔PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
📍 Hartford Healthcare Alliance (Data Collection Only) — Hartford, Connecticut
View Study & Checklist ➔A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
📍 UC San Diego — La Jolla, California
View Study & Checklist ➔A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
📍 Cancer and Blood Specialty clinic — Long Beach, California
View Study & Checklist ➔A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
📍 UC San Diego — La Jolla, California
View Study & Checklist ➔A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
📍 Local Institution - 0007 — Anchorage, Alaska
View Study & Checklist ➔XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
View Study & Checklist ➔Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)
📍 London Regional Cancer Program — London, Ontario
View Study & Checklist ➔A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
📍 GSK Investigational Site — Los Angeles, California
View Study & Checklist ➔Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma
📍 Rhode Island Hospital and The Miriam Hospital — Providence, Rhode Island
View Study & Checklist ➔Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
📍 Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
View Study & Checklist ➔Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
📍 University of South Alabama — Mobile, Alabama
View Study & Checklist ➔Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔Axitinib + Ipilimumab in Advanced Melanoma
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
📍 Local Institution - 0010 — Tucson, Arizona
View Study & Checklist ➔Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
📍 Highlands Oncology Group ( Site 1943) — Springdale, Arkansas
View Study & Checklist ➔